Pimecrolimus - A safe and effective local immunomodulator in the treatment of inflammatory skin diseases

Acta Dermatovenerologica Croatica

Volumn 13, Issue 1, 2005, Pages 63-69

  Lipozenčić, Jasna ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Ascomycin; Elidel ; Immunosuppression; Pimecrolimus

Indexed keywords

BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; PIMECROLIMUS; PLACEBO; TACROLIMUS; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BURNING SENSATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PILOT STUDY; POISON IVY; PRURITUS; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SKIN ALLERGY; SKIN ATROPHY; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ARTICLE; CHRONIC DISEASE; INFLAMMATION; SKIN DISEASE;

CHRONIC DISEASE; DERMATITIS, ATOPIC; ECZEMA; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; PSORIASIS; SKIN DISEASES; TACROLIMUS;

EID: 20344387225     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and application in dermatology. Clin Exp Dermatol 2002;27:555-61.
2. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002;12:618-22.
3. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online 2004;10:3.
4. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-64.
5. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87.
6. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-41.
7. Lazarous MC, Kerdel FA. Topical tacrolimus Pro-topic. Drugs Today (Barc) 2002;38:7-15.
8. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003;17:493-503.
9. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatosis. J Eur Acad Dermatol Venerol 2002;16:100-14.
10. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998;134:1101-2.
11. Remitez A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7.
12. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. A microplaque assay-based, double-blind trial to compare the efficacy of two tacrolimus ointment formulations with two active and two negative controls in patients with chronic plaque-type psoriasis vulgaris. Br J Dermatol 1996;135:833.
13. Yamamoto T, Nishioka K. Deep dermatophytosis during topical tacrolimus therapy for psoriasis. Acta Derm Venerol 2003;83:291-2.
14. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin disease. Expert Opin Invest Drugs 2000;9:69-77.
15. Paul C, Ho VC. Ascomycins in dermatology. Semin Cutan Med Surg 1998;17:256-9.
16. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.
17. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3.
18. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8.
19. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94.
20. Quatresooz P, Fumal I, Pierard-Franchimont C, Pierard GE. Medication of the month. Topical pimecrolimus (Elidel). Rev Med Liege 2003;58:168-71.
21. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-68.
22. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in moderate atopic dermatitis. Dermatology 2004;208:365-72.
23. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004;15:169-78.
24. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-73.
25. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.
26. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:32.
27. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004;5:643-55.
28. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-7.
29. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
30. Papp K, Staab D, Harper J, Potter P, Puig L, Ortonne JP, et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis, Int J Dermatol 2004;43:978-83.
31. Eichenfield LF, Lucky AW, Langley RG, Lyndl Ch, Kaufman R, Todd G, et al. Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children; the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005;44:70-5.
32. Belsito DV, Fowler JF Jr, Marks JG Jr, Pariser DM, Hanifin J, Duarte IA, Pires MC, Cruz PD Jr, Langley RG, Patel P, Bush C, Thurston M, Graeber M, Cherill R; Multicenter Investigator Group. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73:31-8.
33. Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91:563-6.
34. Lipozenčić J. Standlone Meeting: Advancing expectations in atopic eczema and beyond. Acta Dermatovenerol Croat 2004;12:221-4.